Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bayer Aktienges ADR
(OP:
BAYRY
)
7.690
+0.020 (+0.26%)
Streaming Delayed Price
Updated: 12:50 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bayer Aktienges ADR
< Previous
1
2
3
4
5
6
Next >
Merck Projects $10 Billion From Its Next Blockbuster Segment; Will It Measure Up?
April 05, 2022
Merck shares hit a six-month high Tuesday on the bullish projection.
Via
Investor's Business Daily
What Stocks Do Well During a Bear Market? 7 Picks for a Downturn
March 16, 2022
These are the best bear market stocks to invest in now. T, BG and CL are some great picks for investors looking to weather the storm.
Via
InvestorPlace
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia
March 15, 2022
Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines."
Via
Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap: Bayer Q4 Earnings
March 01, 2022
Bayer (OTC:BAYRY) reported its Q4 earnings results on Tuesday, March 1, 2022 at 01:30 AM. Here's what investors need to know about the announcement. Earnings Bayer beat...
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
August 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...
Via
Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
February 17, 2022
Can the formerly red-hot biotech segment return to its previous glory?
Via
Investor's Business Daily
Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer
February 15, 2022
Aveo Pharmaceuticals Inc (NASDAQ: AVEO) will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022...
Via
Benzinga
Why Are Evotec Shares Trading Lower On Friday?
February 04, 2022
Bayer AG (OTC: BAYRY) has
Via
Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
January 13, 2022
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?
Via
Investor's Business Daily
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
January 10, 2022
Pfizer and Bayer inked deals with several companies in gene-editing.
Via
Investor's Business Daily
Corporate Cannabis Takeover? Assessing 5 Big Industries Already At The Table
December 23, 2021
This article was originally published on The Bluntness, and ...
Via
Benzinga
Recursion, Bayer Expand Fibrosis Pact To Include Inferential Search Capabilities
December 06, 2021
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) expanded its existing strategic collaboration in fibrosis with Bayer AG (OTC: BAYRY). The expanded...
Via
Benzinga
Even Good Penny Stocks Like Senseonics Aren’t Always Profitable
December 03, 2021
Its latest implanted sensor lasts six months, but SENS stock faces competition from Dexcom, Abbott Labs and potentially one big name in tech.
Via
InvestorPlace
Bayer's Nubeqa Shows Prolonged Survival In Late-Stage Prostate Cancer Trial
December 03, 2021
Bayer AG (OTC: BAYRY) said a combination therapy, including its Nubeqa drug, was shown to prolong the lives of men who have metastatic prostate cancer in a clinical...
Via
Benzinga
Microsoft, Bayer Collaborate To Develop Digital Agricultural Tools, Capabilities
November 17, 2021
Microsoft Corp (NASDAQ: MSFT) and Bayer AG (OTC: BAYRY) (OTC: BAYZF) collaborated on new internet-based products aimed at helping farmers and industries...
Via
Benzinga
The Secret To Successful Investing In Biotech
October 19, 2021
Have you ever had a stock jump 30%, 50% or 100% in one day?
Via
Talk Markets
Agricultural Technology Companies Are Finding Themselves in a Global Race to Develop and Acquire New Intellectual Property
October 18, 2021
Image by AgriFORCE The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga...
Via
Benzinga
The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
October 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Adcom Recommends Approval Of Moderna's COVID-19 Vaccine Booster Shot For...
Via
Benzinga
Exposures
COVID-19
Product Safety
Here’s What Happens When You Beat The Market By 5% (And How To Do It)
October 11, 2021
See, the way Wall Street makes money has fundamentally shifted in recent years. So has the way information flows to individual investors. And today I want to show you how savvy stock pickers can profit...
Via
Talk Markets
I See Another “Chipotle Moment”
September 27, 2021
Lawsuits are terrible for business. They bring distractions, extra costs, and uncertainty. Big Tobacco knows this all too well.
Via
Talk Markets
Topics
Lawsuit
Exposures
Financial
Legal
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
September 27, 2021
A biotech working in lung and blood diseases, as well as cancer, could be acquired.
Via
Investor's Business Daily
BWXT Medical, Bayer AG Ink Agreement On Actinium-225
September 16, 2021
BWX Technologies Inc's (NYSE: BWXT) subsidiary BWXT Medical Ltd. has agreed with Bayer AG (OTC: BAYRY) to develop Actinium-225 (Ac-225) supply and...
Via
Benzinga
Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration
August 24, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) revealed new Phase 2 proof-of-concept trial data on Eylea (aflibercept) injection in patients with wet age-related...
Via
Benzinga
Berkeley Lights, Bayer Ink Discovery Pact For Next-Gen Traits In Agricultural Sector, Berkeley Q2 Earnings Miss Estimates
August 11, 2021
Berkeley Lights Inc (NASDAQ: BLI) reports Q2 sales of $19.3 million, +82% Y/Y, but slightly missing the consensus of $19.64 million. The Company expanded the installed...
Via
Benzinga
Topics
Earnings
Exposures
Financial
3 Pharma Stocks to Buy in August
August 11, 2021
These stocks offer solid growth opportunities.
Via
The Motley Fool
Bristol Myers Pulls Accelerated Approval For Opdivo In Post-Nexavar Liver Cancer
July 26, 2021
Bristol Myers Squibb & Co (NYSE: BMY) on Friday said it's voluntarily withdrawing Opdivo's approval in hepatocellular carcinoma (HCC) patients who...
Via
Benzinga
The Cloud Sector Can Drive Your Profits Sky High
July 21, 2021
If you hear someone suggesting you invest in “containers,” please don’t get confused. Most folks would naturally think of these as giant metal shipping boxes that are integral for global trade.
Via
Talk Markets
Merck - Bayer's Heart Failure Treatment, Verquvo Scores European Nod
July 21, 2021
The European Commission (EC) has approved Merck & Co Inc's (NYSE: MRK) soluble guanylate cyclase (sGC) stimulator Verquvo (vericiguat). Verquvo...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.